Therapeutic efficacy of FASN inhibition in preclinical models of HCC.
Sign Up to like & getrecommendations! Published in 2022 at "Hepatology"
DOI: 10.1002/hep.32359
Abstract: BACKGROUND & AIMS Aberrant activation of fatty acid synthase (FASN) is a major metabolic event during the development of HCC. We evaluated the therapeutic efficacy of TVB3664, a novel FASN inhibitor, either alone or in… read more here.
Keywords: hcc treatment; tvb3664; efficacy fasn; therapeutic efficacy ... See more keywords